ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 779

Toll-like Receptor 2 Agonism Induces Inflammation, Angiogenesis and Cell Migration in Giant Cell Arteritis

Lorraine O'Neill1, Aoife Maher1, Jennifer McCormick2, Conor Murphy3, Geraldine M. McCarthy4, Douglas J. Veale5, Ursula Fearon2 and Eamonn S. Molloy1, 1Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 2Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, 3Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, 4Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 5Translational Rheumatology Research Group, St. Vincent's University Hospital, Dublin 4, Ireland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: giant cell arteritis, toll-like receptors and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Activation of dendritic cells (DCs) is one of the earliest inciting events in Giant Cell Arteritis (GCA). TLR 2 is expressed on DCs in normal temporal arteries and is also found ubiquitously throughout the macro vasculature. 1 Stimulating temporal arteries implanted into SCID mice with TLR 2 activates dendritic cells. 2 Therefore TLR 2 is likely to play a major role in the pathogenesis of GCA while the exact mechanisms involved are yet to be fully elucidated. 

This study examines the functional effects of TLR 2 on induction of pro-inflammatory cytokines, angiogenesis and cell migration in GCA.

Methods

15 patients with biopsy proven GCA and meeting 1990 ACR classification criteria for GCA were prospectively recruited.  To directly examine the effects of TLR 2 on pro-inflammatory cytokines, growth factors and gelatinase expression in GCA, ex-vivo temporal artery (TA) whole tissue explant models were established. PBMCs and TA explants were cultured in the presence of Pam3CSK4 (a TLR 2 agonist) (1μg/ml) for 24 hours. Supernatants were harvested and assayed for IL-6, IL-8 Ang2, and VEGF by ELISA and MMP-2 and MMP-9 by gelatin zymography. Endothelial cell tube formation was assessed following culture with TLR 2-induced TA explant conditioned media. To examine the effect of TLR 2 on migration/invasion in GCA, TA explants were embedded in Matrigel, stimulated with Pam3CSK4 and myofibroblast outgrowths observed.  Myofibroblasts were also isolated from TA explants, cultured and wound repair assays performed. To examine the effects of TLR 2 on cytoskeletal architecture, cultured myofibroblasts were treated with Pam3CSK4 and stained for F-actin.

Results

In PBMC cultures, Pam3CSK4 induced a 7.7 and 3.6 fold increase in expression of IL6 and IL8 respectively, from a basal IL-6 level of 34.58 ± 6.77 pg/ml to 266.1 ± 117.6 pg /ml and basal IL-8 level of 1769 ± 731.7 pg/ml to 6388 ± 1632 pg/ml.

 In temporal artery explant cultures stimulation with Pam3CSK4 increased expression of IL- 6 from 26,800 ± 9209 pg/ml to 47494 ± 10,946pg/ml (p=0.01). Expression of IL-8 was also increased from basal levels of 20,593 ± 8224 pg/ml to 40,793 ± 16, 670 pg/ml (p=0.058).

Stimulation with Pam3CSK4 significantly increased Ang 2 expression from basal levels of 727.9 ± 254.5 pg/ml to 1415 ± 459.6 pg/ml (p=0.011). There was a trend towards increased expression of VEGF, from basal levels of 107.5 ± 33.38 pg/ml to 200 ± 69.95pg/ml but this was not statistically significant. (p=0.19) Differential effects for MMP2/9 expression were observed on zymography. Pam3CSK4 induced endothelial cell tube formation. Pam3CSK4 also promoted myofibroblast outgrowths from the TA explants and cytoskeletal disassembly in the cultured myofibroblasts. 

Conclusion

In an ex vivo temporal artery culture model, Pam3CSK4, a TLR 2 agonist, enhances production of pro inflammatory mediators, promotes angiogenesis, myofibroblast migration and cytoskeletal rearrangement. TLR2 signalling may therefore play a role in driving vascular inflammation and remodelling in GCA, and may represent a potential therapeutic target in GCA.

1 Pryshchep et al, Circulation 2008

2 Makrupa et al, Journal of Exp Med 2006


Disclosure:

L. O’Neill,
None;

A. Maher,
None;

J. McCormick,
None;

C. Murphy,
None;

G. M. McCarthy,
None;

D. J. Veale,
None;

U. Fearon,
None;

E. S. Molloy,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/toll-like-receptor-2-agonism-induces-inflammation-angiogenesis-and-cell-migration-in-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology